Sintilimab

Sintilimab is a monoclonal antibody used in the treatment of various types of cancer. It is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking this pathway, sintilimab helps to restore the immune system's ability to recognize and destroy cancer cells.

Mechanism of Action[edit]

Sintilimab is a fully human IgG4 monoclonal antibody that binds to the PD-1 receptor on T cells. The PD-1 receptor is an immune checkpoint that, when engaged by its ligands PD-L1 or PD-L2, inhibits T cell activation and allows cancer cells to escape immune surveillance. By inhibiting the interaction between PD-1 and its ligands, sintilimab reactivates T cells, enabling them to attack and kill cancer cells.

Clinical Applications[edit]

Sintilimab has been approved for use in several types of cancer, including:

Clinical trials are ongoing to evaluate its efficacy in other malignancies, such as esophageal cancer and hepatocellular carcinoma.

Development and Approval[edit]

Sintilimab was developed by Innovent Biologics in collaboration with Eli Lilly and Company. It was first approved in China in 2018 for the treatment of relapsed or refractory classical Hodgkin's lymphoma. Since then, its indications have expanded, and it is being studied in combination with other therapies to enhance its effectiveness.

Side Effects[edit]

As with other immune checkpoint inhibitors, sintilimab can cause immune-related adverse events (irAEs) due to increased immune activity. Common side effects include:

Fatigue
Rash
Diarrhea
Hepatitis
Pneumonitis

Severe irAEs may require treatment with corticosteroids or other immunosuppressive agents.

Research and Future Directions[edit]

Ongoing research is focused on identifying biomarkers that predict response to sintilimab, optimizing combination therapies, and expanding its use to additional cancer types. Studies are also exploring its role in the neoadjuvant and adjuvant settings.

Also see[edit]